Clinical Trials Logo

Clinical Trial Summary

Repeated joint bleeding leads to hemophilic arthropathy (HA), which manifests with chronic synovitis, cartilage damage and bony destruction. Currently available treatments of HA, including analgesics, NSAIDs, and hyaluronic acid, are predominantly directed toward the symptomatic relief of pain and inflammation, with no or little effect on joint cartilage degeneration. AC201CR, a control released formulation of AC-201, demonstrates anti-inflammatory effects by reducing NLRP3 inflammasome assembly. AC-201 is also unique in that it influences both the anabolism and catabolism of chondrocytes in vitro and has shown cartilage-sparing properties in animal studies. The study is designed to evaluate the joint structure-modifying and symptom-relieving effects, safety, and tolerability of AC-201CR in subjects with HA.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT02994147
Study type Interventional
Source TWi Biotechnology, Inc.
Status Completed
Phase Phase 2
Start date March 21, 2017
Completion date October 2, 2019

See also
  Status Clinical Trial Phase
Completed NCT01232634 - Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles Phase 2
Completed NCT02601170 - Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy N/A
Recruiting NCT04684511 - Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy Phase 3
Completed NCT04297696 - The Effects of Exercises on Gait in Hemophilic Individuals N/A
Completed NCT04535180 - Sarcopenia and Osteoporosis in the Patients With Hemophilia
Terminated NCT02569359 - Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy N/A